Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel in Advanced Cutaneous SCC
NCT02076243Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in cutaneous squamous cell carcinoma (cSCC), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Response Rate at 8 weeks. Started Mar 2014; status: terminated.
02
Drugs
paclitaxel
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT02076243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076243.